Crizotinib (PF-02341066)

Suppliers

Names

[ Name ]:
Crizotinib (PF-02341066)

[Synonym ]:
Crizotinib
Xalkori
3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine
3-[(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-2-pyridinamine
(R)-3-(1-(2,6-Dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine
3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]pyridin-2-amine
2-Pyridinamine, 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-
(R)-Crizotinib
PF-2341066
PF2341066

Chemical & Physical Properties

[ Density]:
1.5±0.1 g/cm3

[ Boiling Point ]:
599.2±50.0 °C at 760 mmHg

[ Molecular Formula ]:
C₂₁H₂₂Cl₂FN₅O

[ Molecular Weight ]:
450.337

[ Flash Point ]:
316.2±30.1 °C

[ Exact Mass ]:
449.118530

[ PSA ]:
77.99000

[ LogP ]:
4.73

[ Vapour Pressure ]:
0.0±1.7 mmHg at 25°C

[ Index of Refraction ]:
1.673

[ Storage condition ]:
-20°C

MSDS

Click to get detail MSDS

Safety Information

[ Symbol ]:

GHS07, GHS08, GHS09

[ Signal Word ]:
Warning

[ Hazard Statements ]:
H317-H319-H341-H400

[ Precautionary Statements ]:
P273-P280-P305 + P351 + P338

[ Hazard Codes ]:
Xi

[ Safety Phrases ]:
24/25

[ RIDADR ]:
UN 3077 9 / PGIII

[ HS Code ]:
2933990090

Customs

[ HS Code ]: 2933990090

[ Summary ]:
2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Articles

Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects.

Xenobiotica 45(1) , 45-59, (2014)

1. Crizotinib (XALKORI®), an oral inhibitor of anaplastic lymphoma kinase (ALK) and mesenchymal-epithelial transition factor kinase (c-Met), is currently approved for the treatment of patients with no...

Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors.

Cancer Res. 75 , 2916-27, (2015)

The anaplastic lymphoma kinase (ALK) is chromosomally rearranged in a subset of certain cancers, including 2% to 7% of non-small cell lung cancers (NSCLC) and ∼70% of anaplastic large cell lymphomas (...

Understanding the Interplay between Expression, Mutation and Activity of ALK Receptor in Rhabdomyosarcoma Cells for Clinical Application of Small-Molecule Inhibitors.

PLoS ONE 10 , e0132330, (2015)

Receptor tyrosine kinases (RTKs) have a central role in cancer initiation and progression, since changes in their expression and activity potentially results in cell transformation. This concept is es...